Scientific article
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
Contributors
Büller, Harry R; Prins, Martin H; Lensing, Anthonie W A; Decousus, Hervé; Jacobson, Barry F; Minar, Erich; Chlumsky, Jaromir; Verhamme, Peter; Wells, Phil; Agnelli, Giancarlo; Cohen, Alexander; Berkowitz, Scott D; Bounameaux, Henri; Davidson, Bruce L; Misselwitz, Frank; Gallus, Alex S; Raskob, Gary E; Schellong, Sebastian; Segers, AnnelisePublished in
The New England journal of medicine, vol. 366, no. 14, p. 1287-1297Publication date
2012Abstract
Keywords
- Administration
- Oral
- Aged
- Anticoagulants/adverse effects/therapeutic use
- Drug Therapy
- Combination
- Enoxaparin/adverse effects/therapeutic use
- Female
- Follow-Up Studies
- Hemorrhage/chemically induced
- Humans
- International Normalized Ratio
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Morpholines/adverse effects/therapeutic use
- Pulmonary Embolism/drug therapy/mortality
- Recurrence
- Thiophenes/adverse effects/therapeutic use
- Treatment Outcome
- Vitamin K/antagonists & inhibitors
UNIGE affiliation entities
UNIGE research groups
Citation (ISO format)
BÜLLER, Harry R et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. In: The New England journal of medicine, 2012, vol. 366, n° 14, p. 1287–1297. doi: 10.1056/NEJMoa1113572
Main files (1)
Article (Published version)
Identifiers
- PID : unige:26316
- DOI : 10.1056/NEJMoa1113572
- PMID : 22449293
